Emergent Biosolutions Inc - Asset Resilience Ratio
Emergent Biosolutions Inc (EBS) has an Asset Resilience Ratio of 15.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Emergent Biosolutions Inc's Asset Resilience Ratio has changed over time. Check Emergent Biosolutions Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Emergent Biosolutions Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EBS company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $205.40 Million | 15.58% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $205.40 Million | 15.58% |
Asset Resilience Insights
- Good Liquidity Position: Emergent Biosolutions Inc maintains a healthy 15.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Emergent Biosolutions Inc Industry Peers by Asset Resilience Ratio
Compare Emergent Biosolutions Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Emergent Biosolutions Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Emergent Biosolutions Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.58% | $205.40 Million | $1.32 Billion | +8.42pp |
| 2024-12-31 | 7.16% | $99.50 Million | $1.39 Billion | +0.57pp |
| 2023-12-31 | 6.59% | $120.20 Million | $1.82 Billion | -13.70pp |
| 2022-12-31 | 20.29% | $642.60 Million | $3.17 Billion | +0.82pp |
| 2021-12-31 | 19.48% | $576.10 Million | $2.96 Billion | -2.07pp |
| 2020-12-31 | 21.55% | $621.30 Million | $2.88 Billion | +14.34pp |
| 2019-12-31 | 7.21% | $167.80 Million | $2.33 Billion | +2.18pp |
| 2018-12-31 | 5.03% | $112.20 Million | $2.23 Billion | -11.72pp |
| 2017-12-31 | 16.76% | $179.34 Million | $1.07 Billion | -11.23pp |
| 2016-12-31 | 27.99% | $271.51 Million | $970.11 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $1.04 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $626.63 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $564.23 Million | -- |
| 2011-12-31 | 0.36% | $1.97 Million | $546.86 Million | -0.05pp |
| 2010-12-31 | 0.41% | $2.03 Million | $500.32 Million | +0.34pp |
| 2009-12-31 | 0.06% | $215.00K | $344.69 Million | -1.75pp |
| 2004-12-31 | 1.81% | $1.25 Million | $69.06 Million | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more